Skip to main content
Equibles

Stonepine Capital Management, LLC

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1440771 BEND, OR
Back to ACAD Full portfolio

Position in ACAD

as of Mar 31, 2026 · filed May 14, 2026
Position Value
$0
-$2,671,000 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record

Common Shares in ACAD Over Time

Shares Held

Position Value (USD)

Derivatives in ACAD

reported options exposure · as of Mar 31, 2026
CallValue
$2,226,000
CallShares
100,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Stonepine Capital Management, LLC holds $108,574,607 across 61 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 VSTM
Verastem, Inc.
 3,349,627 $12,795,575
2 TENX
Tenax Therapeutics, Inc.
 660,000 $9,603,000
3 NKTR
Nektar Therapeutics
 120,654 $8,422,855
4 ADMA
Adma Biologics, Inc.
 740,000 $6,193,800
5 CAMP
Camp4 Therapeutics Corp
 1,389,622 $6,072,648
6 ELOX
Eloxx Pharmaceuticals, Inc.
 397,160 $5,512,580
7 KZIA
Kazia Therapeutics Ltd
 345,179 $4,860,120
8 CRBP
Corbus Pharmaceuticals Holdings, Inc.
 425,000 $3,986,500

All Filings in ACAD

Export CSV
8 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $2,226,000 100,000
2025-12-31 $2,671,000 100,000
2025-09-30 $3,724,768 174,544
2025-06-30 $4,853,250 225,000
2025-03-31 $185,850 93,393
2024-12-31 $4,037,000 220,000
2024-09-30 $3,028,245 196,895
2024-06-30 $81,250 5,000